A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Clinical trial NCT04955938 · WITHDRAWN

Trial details

NCT number: NCT04955938
Sponsor: University of Chicago
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

IDH Mutation IDH1 Mutation IDH2 Gene Mutation Blood Cancer Myeloproliferative Neoplasm

Start date: 2021-10-29
Primary completion: 2023-06-07
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.